Eli Lilly and Company representatives recently presented Phase 3 study results for the advanced urothelial carcinoma treatment Cyramza (ramucirumab) at an international summit, stating that data indicate improved survival chances in those patients treated with ramucirumab and docetaxel.
Lilly presented the information regarding a randomized, placebo-controlled study at a symposium during the recent European Society for Medical Oncology (ESMO) 2017 Congress held in Spain. Results were expected to be published in The Lancet as well.
"It's been an exciting and eventful time in urothelial carcinoma medicine research and development over the last several years, going from very few approved therapies to many new treatment options now available this year,” Dr. Daniel Petrylak, professor of medical oncology and urology at Yale Cancer Center and principal investigator, said in a Lilly release.
Petrylak said the Phase 3 study results were the first to indicate an advantage in fighting angiogenesis in urothelial cancer and that ramucirumab is “the first therapy to show superior progression-free survival over chemotherapy in a post-platinum setting” as well as to provide validation for a previous study.
"We are encouraged by these results … as patients with this aggressive type of cancer who experience disease progression urgently need additional treatment options that can help stop or slow the cancer from growing and spreading," Dr. Levi Garraway, senior vice president for global development and medical affairs at Lilly Oncology, said in the release.